← Back to Search

Other

CCT-102 Regimen for Miscarriage (MERMAID Trial)

Phase 3
Recruiting
Research Sponsored by Conceptra Biosciences, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 to 50
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights

MERMAID Trial Summary

This trial is testing a new treatment called CCT-102 for women who have a delayed pregnancy loss in the first trimester. The trial will compare the CCT-102 treatment to standard expectant management to

Who is the study for?
This trial is for women aged 18 to 50 who have experienced a non-progressing miscarriage in the first trimester. Participants must be stable, able to consent, and have specific clinical signs of early pregnancy loss with no more than 10 weeks gestation.Check my eligibility
What is being tested?
The study compares CCT-102 A and CCT-102 B treatments against waiting for natural resolution in cases of delayed pregnancy loss. It aims to see if these treatments can help clear the uterus more effectively than expectant management.See study design
What are the potential side effects?
Potential side effects are not detailed here but may include symptoms related to medication-induced uterine evacuation such as cramping, bleeding, nausea, or emotional distress.

MERMAID Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 50 years old.

MERMAID Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Resolution of pregnancy loss

MERMAID Trial Design

2Treatment groups
Active Control
Group I: CCT-102 RegimenActive Control1 Intervention
CCT-102 A/B regimen
Group II: Expectant managementActive Control1 Intervention
Non-treatment, 'waitful watching'

Find a Location

Who is running the clinical trial?

Conceptra Biosciences, LLCLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available vacancies for patient participation in this clinical trial?

"Indeed, the information on clinicaltrials.gov indicates that this particular clinical trial is actively seeking eligible participants. The trial was initially posted on December 15th, 2023 and had its most recent update on January 5th, 2024. A total of 160 patients will be enrolled in this study across eight different locations."

Answered by AI

How many medical facilities are currently conducting this research trial?

"At present, this clinical trial is actively enrolling patients from a total of 8 sites. These sites are situated in various cities including Norfolk, San Diego, Idaho Falls, and 5 other locations. To minimize travel obligations for participants who enroll, it is advisable to select the site closest to their location."

Answered by AI

Which individuals are eligible to partake in this experimental study?

"To be eligible for enrollment in this clinical trial, individuals must have a history of miscarriage and fall within the age range of 18 to 50. The study aims to recruit a total of 160 participants."

Answered by AI

What is the current total number of participants being recruited for this clinical study?

"To conduct this research, the sponsor Conceptra Biosciences, LLC will be overseeing the trial at multiple locations. Specifically, Tidewater Clinical Research in Norfolk, Virginia and A&B Clinical Research, Inc. in San Diego, California are among them. In order to proceed with the study as planned a total of 160 eligible participants who meet the inclusion criteria need to be enrolled."

Answered by AI

Has the CCT-102 Regimen received official approval from the FDA?

"Based on the information provided, our team at Power assesses the safety of CCT-102 Regimen to be a 3. This determination is based on it being a Phase 3 trial, indicating that there is existing evidence supporting its effectiveness and multiple rounds of data affirming its safety."

Answered by AI

Is the participation in this study open to individuals aged 75 years and above?

"To be eligible for participation in this study, individuals must fall within the age range of 18 to 50. It is important to note that there are separate clinical trials available specifically for patients under the age of 18 (3 trials) and those over the age of 65 (7 trials)."

Answered by AI

Who else is applying?

What site did they apply to?
University Hospitals Cleveland Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
CCT-102 vs. Expectant Management in Delayed Pregnancy Loss
2023. "CCT-102 vs. Expectant Management in Delayed Pregnancy Loss". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06121063.
All > Miscarriage > Vancouver
~32 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top